FDA clears masitinib IND in Amyotrophic Lateral Sclerosis, allowing U.S. patient enrollment to commence in Phase 3 study

31/03/2020 – AB Science today announces that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application, allowing the Company to initiate its masitinib Phase 3 study (AB19001) in amyotrophic lateral sclerosis